📰 Hematocrit Control News
Hematocrit Control News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hematocrit Control. Real-time updates on events, politics, business and more.
May 15, 2024
NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Associatio...
November 2, 2023
Protagonist Reports Third Quarter 2023 Financial Results and Provides ...
November 2, 2023
Protagonist Therapeutics Announces Abstracts Selected for Oral and ...
November 2, 2023
– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines – Plenary Scientific Session will feature...
November 2, 2023
Five rusfertide abstracts accepted for oral and poster presentations at the 65th ASH Annual Meeting and Exposition (ASH2023)Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first- and only-in-class oral ...
November 2, 2023
02.11.2023 - Five rusfertide abstracts accepted for oral and poster presentations at the 65th ASH Annual Meeting and Exposition (ASH2023)Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first- and only-in-class oral ...